keyword
https://read.qxmd.com/read/38581543/the-investigation-of-the-subtle-structural-discrepancies-between-oryza-sativa-recombinant-and-plasma-derived-human-serum-albumins-to-design-a-novel-nanoparticle-as-a-taxane-delivery-system
#21
JOURNAL ARTICLE
Ru Fang, Liang He, Yanbin Wang, Liling Wang, Hua Qian, Shaozong Yang
To solve the large size faultiness of Oryza sativa recombinant human serum albumin nanoparticle (OsrHSA NP), the structural discrepancies between OsrHSA and plasma-derived human serum albumin (pdHSA) were analyzed deeply in this research. It demonstrated that there were some subtle structural discrepancies located in subdomain IA and IIA between OsrHSA and pdHSA, which included peptide backbone, disulphide bridge and some amino acids. Firstly, the structural discrepancies were investigated through literature comparison, it inferred that the structural discrepancies resulted from the fatty acid (FA) binding to OsrHSA at site 2 of subdomain IA and IIA...
April 6, 2024: Protein Journal
https://read.qxmd.com/read/38577141/circulating-mirna-21-levels-in-breast-cancer-patients-before-and-after-chemotherapy-and-its-association-with-clinical-improvement
#22
JOURNAL ARTICLE
Sanchi Sukhija, Purvi Purohit, Puneet Pareek, Pawan Kumar Garg, Jeewan Ram Vishnoi, Poonam Abhay Elhence, Shobhan Babu Varthya, Praveen Sharma, Sneha Ambwani, Jaykaran Charan
Breast cancer is the most frequent type of cancer in women, many patients experience recurrences and metastasis. miR-21 (microRNA-21) as biomarker is under investigation for breast cancer. At present, there is very limited information available regarding effect of chemotherapy on miR-21 expression in breast cancer and its correlation with the clinical improvement. Hence, this study was planned to evaluate the effect of chemotherapy on miR-21 in metastatic breast cancer and its relationship with the clinical outcome...
April 2024: Indian Journal of Clinical Biochemistry: IJCB
https://read.qxmd.com/read/38576013/exploring-the-effectiveness-of-molecular-subtypes-biomarkers-and-genetic-variations-as-first-line-treatment-predictors-in-asian-breast-cancer-patients-a-systematic-review-and-meta-analysis
#23
JOURNAL ARTICLE
Nurul Wafiqah Saipol Bahrin, Siti Nur Idayu Matusin, Aklimah Mustapa, Lu Zen Huat, Sriyani Perera, Mas Rina Wati Haji Abdul Hamid
BACKGROUND: Breast cancer incidence has been on the rise significantly in the Asian population, occurring at an earlier age and a later stage. The potential predictive value of molecular subtypes, biomarkers, and genetic variations has not been deeply explored in the Asian population. This study evaluated the effect of molecular subtype classification and the presence or absence of biomarkers and genetic variations on pathological complete response (pCR) after neoadjuvant treatment in Asian breast cancer patients...
April 4, 2024: Systematic Reviews
https://read.qxmd.com/read/38575662/cyp2c8-rs11572080-and-cyp3a4-rs2740574-risk-genotypes-in-paclitaxel-treated-premenopausal-breast-cancer-patients
#24
JOURNAL ARTICLE
Hanaa R M Attia, Mahmoud M Kamel, Dina F Ayoub, Shereen H Abd El-Aziz, Mai M Abdel Wahed, Safa N Abd El-Fattah, Mahmoud A Ablel-Monem, Thanaa M Rabah, Amany Helal, Mona Hamed Ibrahim
Breast cancer (BC) is the most prevalent malignancy in women globally. At time of diagnosis, premenopausal BC is considered more aggressive and harder to treat than postmenopausal cases. Cytochrome P450 (CYP) enzymes are responsible for phase I of estrogen metabolism and thus, they are prominently involved in the pathogenesis of BC. Moreover, CYP subfamily 2C and 3A play a pivotal role in the metabolism of taxane anticancer agents. To understand genetic risk factors that may have a role in pre-menopausal BC we studied the genotypic variants of CYP2C8, rs11572080 and CYP3A4, rs2740574 in female BC patients on taxane-based therapy and their association with menopausal status...
April 4, 2024: Scientific Reports
https://read.qxmd.com/read/38571693/does-post-mastectomy-radiotherapy-confer-survival-benefits-on-patients-with-1-3-clinically-positive-lymph-nodes-rendered-pathologically-negative-after-neoadjuvant-systemic-chemotherapy-consensus-from-a-pooled-analysis
#25
Munaser Alamoodi
The advent of taxane-based chemotherapy has revolutionized breast cancer care. This advance has helped improve the response to downstaging tumors that might otherwise be inoperable. It has also helped in rendering clinically (cN+) positive lymph nodes (LNs) pathologically negative (ypN0). The standard of care for cN+ patients included post-mastectomy radiotherapy (PMRT), regardless of the response to neoadjuvant chemotherapy. However, PMRT in patients with 1-3 positive LNs still lacks definitive guidelines...
April 2024: European Journal of Breast Health
https://read.qxmd.com/read/38570028/chemo-senolytic-therapeutic-potential-against-angiosarcoma
#26
JOURNAL ARTICLE
Xuebing Wang, Claire Yik-Lok Chung, Ai Yoshioka, Shinya Hashimoto, Haruki Jimbo, Hideki Tanizawa, Shinya Ohta, Takeshi Fukumoto, Ken-Ichi Noma
Angiosarcoma is an aggressive soft-tissue sarcoma with a poor prognosis. Chemotherapy for this cancer typically employs paclitaxel, a taxane (genotoxic drug), although it has a limited effect owing to chemoresistance to prolonged treatment. Here, we examine an alternative angiosarcoma treatment approach that combines chemotherapeutic and senolytic agents. We find that the chemotherapeutic drugs cisplatin and paclitaxel efficiently induce senescence in angiosarcoma cells. Subsequent treatment with the senolytic agent ABT-263 eliminates senescent cells by activating the apoptotic pathway...
April 1, 2024: Journal of Investigative Dermatology
https://read.qxmd.com/read/38568074/efficacy-of-adjuvant-capecitabine-in-residual-triple-negative-breast-cancer-a-multicenter-observational-turkish-oncology-group-tog-study
#27
JOURNAL ARTICLE
Elif Şenocak Taşçı, Yasin Kutlu, Ömer Fatih Ölmez, Arda Ulaş Mutlu, Yasemin Gündoğdu, Mustafa Seyyar, Elif Şahin, Devrim Çabuk, Nargiz Majidova, İrem Uğurlu, Ayşe Demirci, Dinçer Aydın, Eyüp Çavdar, Selami Bayram, Nilgün Yıldırım, Fatih Karataş, Melek Karakurt Eryılmaz, Dilek Çağlayan, Serkan Menekşe, Engin Kut, Hacı Arak, Murat Keser, Veli Sunar, Perihan Perkin, Teoman Şakalar, Başak Oyan, Özlem Sönmez, Leyla Özer, İbrahim Yıldız
BACKGROUND: Triple negative breast cancer (TNBC) is characterized by high rates of recurrence, especially in patients with residual disease after neoadjuvant chemotherapy (NAC). Capecitabine is being used as standard adjuvant treatment in residual TNBC. We aimed to investigate the real-life data regarding the efficacy of capecitabine in residual TNBC. DESIGN AND METHODS: In this retrospective multicenter study, TNBC patients with residual disease were evaluated...
April 3, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38563976/time-dependent-changes-of-extremity-volume-and-tissue-alterations-in-swollen-arms-caused-by-taxanes
#28
JOURNAL ARTICLE
Kotaro Suehiro, Noriyasu Morikage, Takasuke Harada, Yuriko Takeuchi, Soichi Ike, Ryunosuke Sakamoto, Ryo Suzuki, Hiroshi Kurazumi, Toshiki Tanaka, Kimikazu Hamano
Background: We aimed to determine the course of arm swelling caused by the use of taxanes and to identify valid predictors of persistent swelling. Methods and Results: A total of 15 patients with unilateral arm swelling that developed during the course, or within 3 months after termination, of postoperative taxane-based chemotherapy were included in the present study. The patients attended follow-up appointments every 3-6 months for 24 months after their initial visit. Their arm circumference was measured at each follow-up appointment, while ultrasonography of the skin and subcutaneous tissues was performed at the 0-, 6-, 12-, and 24-month follow-ups...
April 2, 2024: Lymphatic Research and Biology
https://read.qxmd.com/read/38561474/therapeutic-effects-of-compression-therapy-on-taxane-induced-peripheral-neuropathy-incidence-negative-emotions-and-sleep-disorders-in-patients-with-breast-cancer
#29
RANDOMIZED CONTROLLED TRIAL
Guo Dongxue, Li Ran, Zhao Fangfei, Zhang Zirui, Zhou Lizhi
PURPOSE: To explore the effects of compression therapy on chemotherapy-induced peripheral neuropathy (CIPN), anxiety, depression, and sleep disorders in breast cancer patients administered taxanes. METHODS: Eighty patients with breast cancer undergoing chemotherapy at Tangshan People's Hospital between October 2022 and July 2023 were randomly divided into control (n = 40) and intervention (n = 40) groups. The control group received routine care, while intervention group received compression therapy in addition to routine care (30 min before the infusion of chemotherapy drugs, patients wore surgical gloves on their hands that were one size smaller than the appropriate size and elastic socks on their feet until 30 min after the infusion)...
April 2, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38553303/chemotherapy-related-trigeminal-and-glossopharyngeal-nerves-neurotoxicity-a-cohort-study
#30
JOURNAL ARTICLE
Antonio Arlen da Silva Freire, Antônio Sérgio Guimarães, Patrícia Leal Dantas Lobo, Luciane Lacerda Franco Rocha Rodrigues
BACKGROUND AND OBJECTIVES: The association between orofacial neurotoxicity and chemotherapy treatment is still unclear. In this context, the purpose of this study is to relate the orofacial alterations that manifest during antineoplastic pharmacological treatment, highlighting the drugs commonly related to orofacial neuropathy and the adequate instrument to verify the alterations at clinical levels. METHODS: This prospective cohort study, addressed patients who would start therapy with taxanes, platinum, or related therapy...
February 22, 2024: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
https://read.qxmd.com/read/38547774/a-three-arm-randomised-phase-ii-study-of-the-mek-inhibitor-selumetinib-alone-or-in-combination-with-paclitaxel-in-metastatic-uveal-melanoma
#31
JOURNAL ARTICLE
Joseph J Sacco, Richard Jackson, Pippa Corrie, Sarah Danson, T R Jeffry Evans, Sebastian Ochsenreither, Satish Kumar, Andrew Goodman, James Larkin, Ioannis Karydis, Neil Steven, Paul Lorigan, Ruth Plummer, Poulam Patel, Eftychia Psarelli, Anna Olsson-Brown, Heather Shaw, Serge Leyvraz, Louise Handley, Charlotte Rawcliffe, Paul Nathan
AIMS: The MAPK pathway is constitutively activated in uveal melanoma (UM). Selumetinib (AZD6244, ARRY-142886), a MEK inhibitor, has shown limited activity as monotherapy in metastatic UM. Pre-clinical studies support synergistic cytotoxic activity for MEK inhibitors combined with taxanes, and here we sought to assess the clinical efficacy of combining selumetinib and paclitaxel. PATIENTS AND METHODS: Seventy-seven patients with metastatic UM who had not received prior chemotherapy were randomised to selumetinib alone, or combined with paclitaxel with or without interruption in selumetinib two days before paclitaxel...
March 11, 2024: European Journal of Cancer
https://read.qxmd.com/read/38547419/real-world-overall-survival-and-treatment-patterns-by-pten-status-in-metastatic-castration-resistant-prostate-cancer
#32
JOURNAL ARTICLE
Shilpa Gupta, Tu My To, Ryon Graf, Edward E Kadel, Norelle Reilly, Husam Albarmawi
PURPOSE: It is estimated that the PTEN tumor suppressor gene is functionally lost in 40%-50% of patients with metastatic castration-resistant prostate cancer (mCRPC). There is limited information on the prognostic significance of PTEN status identified with genomic testing. This real-world cohort study assessed PTEN as a genetic biomarker using data from US-based oncology practices. METHODS: This retrospective real-world cohort study used a deidentified US-based metastatic prostate cancer clinicogenomic database linked to longitudinal clinical data derived from electronic health records...
March 2024: JCO Precision Oncology
https://read.qxmd.com/read/38539490/management-of-patients-with-hypersensitivity-to-platinum-salts-and-taxane-in-gynecological-cancers-a-cross-sectional-study-by-the-european-network-of-young-gynaecologic-oncologists-enygo
#33
JOURNAL ARTICLE
Tibor A Zwimpfer, Esra Bilir, Khayal Gasimli, Andrej Cokan, Nicolò Bizzarri, Zoia Razumova, Joanna Kacperczyk-Bartnik, Tanja Nikolova, Andrei Pletnev, Ilker Kahramanoglu, Alexander Shushkevich, Aleksandra Strojna, Charalampos Theofanakis, Tereza Cicakova, Marcus Vetter, Céline Montavon, Gilberto Morgan, Viola Heinzelmann-Schwarz
Platinum and taxane chemotherapy is associated with the risk of hypersensitivity reactions (HSRs), which may require switching to less effective treatments. Desensitization to platinum and taxane HSRs can be used to complete chemotherapy according to the standard regimen. Therefore, we aimed to investigate the current management of HSRs to platinum and/or taxane chemotherapy in patients with gynecologic cancers. We conducted an online cross-sectional survey among gynecological and medical oncologists consisting of 33 questions...
March 14, 2024: Cancers
https://read.qxmd.com/read/38538968/real-world-experience-with-pertuzumab-and-trastuzumab-combined-with-chemotherapy-in-neoadjuvant-treatment-for-patients-with-early-stage-her2-positive-breast-cancer-the-neopersur-study
#34
JOURNAL ARTICLE
Alejandro Falcón González, Josefina Cruz Jurado, Elisenda Llabrés Valenti, Rocío Urbano Cubero, Maria Carmen Álamo de la Gala, María Antonia Martínez Guisado, Rocío Álvarez Ambite, Carlos José Rodríguez González, Marta Amérigo Góngora, Lourdes Rodríguez Pérez, Pilar López Álvarez, Pedro Sánchez Rovira, Encarnación González Flores, Fernando Henao Carrasco, Juan Bayo Calero, María Valero Arbizu, Alicia Quílez Cutillas, Javier Salvador Boffil, Eloísa Rubio Pérez, Manuel Ruiz-Borrego
PURPOSE: HER2-targeted therapies have dramatically improved outcomes of patients with HER2-positive breast cancer (BC), as demonstrated in neoadjuvant trials. This study aims to provide real-world evidence on the use and effectiveness of combined pertuzumab, trastuzumab and chemotherapy (CT) in early-stage HER2-positive BC. METHODS: A retrospective, multicentre study was conducted on patients diagnosed with HER2-positive early BC treated with neoadjuvant pertuzumab and trastuzumab plus CT at 13 Spanish sites...
March 28, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38534939/-177-lu-psma-617-in-metastatic-castration-resistant-prostate-cancer-a-review-of-the-evidence-and-implications-for-canadian-clinical-practice
#35
REVIEW
Kim N Chi, Steven M Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J Hotte, David T Laidley, Fred Saad
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177 Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant prostate cancer (mCRPC). As this treatment represents a new therapeutic class, guidance regarding how to integrate it into clinical practice is needed. This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177 Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice...
March 7, 2024: Current Oncology
https://read.qxmd.com/read/38528382/hypersensitivity-reactions-to-taxanes-a-multicenter-study-for-outcomes-and-safety-of-rapid-drug-desensitization
#36
JOURNAL ARTICLE
Makbule Seda Bayrak Durmaz, Done Gulcin Unutmaz, Meryem Demir, Ozlem Goksel, Adile Berna Dursun, Sevim Bavbek
PURPOSE: Taxanes can cause hypersensitivity reactions (HSRs), which pose a significant challenge in the treatment of malignancies. Patients who are eligible for rapid drug desensitization (RDD) can continue treatment; however, some patients experience breakthrough reactions (BTRs). Data about risk factors for BTRs during RDDs in patients with HSRs to taxanes are limited. METHODS: This was a multicenter, retrospective study of patients with immediate-HSRs to taxanes...
March 2024: Allergy, Asthma & Immunology Research
https://read.qxmd.com/read/38528379/understanding-and-challenging-of-taxane-hypersensitivity
#37
EDITORIAL
Kyung Hee Park
No abstract text is available yet for this article.
March 2024: Allergy, Asthma & Immunology Research
https://read.qxmd.com/read/38528295/a-real-world-study-of-treatment-sequences-and-second-line-clinical-outcomes-in-patients-with-her2-positive-metastatic-breast-cancer-in-us-community-practice
#38
JOURNAL ARTICLE
Della Varghese, Giovanna I Cruz, Colden Johanson, Liz Toland, Miguel Miranda, Eleanor C Faherty, David Harland, Henry G Kaplan
PURPOSE: Standard-of-care for HER2-positive metastatic breast cancer (HER2 + mBC) patients consists of trastuzumab ± pertuzumab with chemotherapy in first-line (1L), and ado-trastuzumab emtansine (T-DM1) or the more recently approved trastuzumab deruxtecan (T-DXd) in second-line (2L). Contemporary data on treatment sequencing and real-world effectiveness is limited. This study aims to report 2L treatments and outcomes among HER2 + mBC patients in the United States (US)...
March 25, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38526855/genetic-determinants-of-taxane-induced-peripheral-neuropathy
#39
JOURNAL ARTICLE
Beata Mladosievicova, Magdalena Nemcokova Jablonicka, Lucia Tatayova, Michal Bernadic
The efficacy of taxane‑containing regimens has been demonstrated for various cancers, particularly ovarian, endometrial, breast, lung, and prostate cancers. However, extensive taxane-induced toxicities limit their use. Prediction and management of many toxic complications in cancer patients have evolved significantly over the last decade. Peripheral neuropathy is the most typical non-hematological taxane-related complication, and it has a multifactorial pathogenesis. It is often dose-dependent and progressive during therapy and sometimes even after treatment...
2024: Bratislavské Lekárske Listy
https://read.qxmd.com/read/38522950/influence-of-cancer-in-pregnancy-on-obstetric-and-neonatal-outcomes-an-observational-retrospective-cohort-study
#40
JOURNAL ARTICLE
Xuan Huang, Chen Zhang, Jialei Zhu, Yueyan Li, Jing Tang
OBJECTIVE: The study aimed to review the oncological characteristics and treatment of pregnancy-associated cancers and analyze the obstetric and neonatal outcomes to provide evidence-based recommendations for reproductive function preservation, oncological treatment, and obstetric management. METHODS: We conducted an observational retrospective cohort study among pregnant patients with cancer in 7 Chinese tertiary A hospitals from 2003 to 2021. We conducted multiple logistic regression to determine the influence of various factors on preterm birth and small-for-gestational-age infants, log-binomial regression to analyze temporal changes, and χ² tests to explore the effects of cancer type/treatment...
March 11, 2024: Journal of Gynecologic Oncology
keyword
keyword
64691
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.